BerGenBio (ONCIN.OL) Stock Analysis & AI Equity Report
BerGenBio (ONCIN.OL) overview
BerGenBio (ONCIN.OL) stock analysis and AI equity research. For the latest completed financial year, 2024, BerGenBio reported revenue of NOK 0.8m and operating profit of NOK -151m; the year-end share price was 8.18 NOK and market capitalisation was NOK 289m. BerGenBio is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BerGenBio's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-12-12. Data will be refreshed during report generation.
About BerGenBio
BerGenBio ASA was a clinical-stage biopharmaceutical company focused on developing therapies targeting the AXL pathway for aggressive diseases, especially cancer, and previously severe respiratory infections. Its lead program was bemcentinib, a selective AXL inhibitor being developed for specific oncology indications. The company was based in Bergen, Norway, with a subsidiary in Oxford, UK.
Generate the BerGenBio report
BerGenBio is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for BerGenBio and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.